Agentix Corp. (AGTX)

OTCMKTS · Delayed Price · Currency is USD
0.0400
-0.0100 (-20.00%)
May 27, 2025, 9:55 AM EDT
12.83%
Market Cap 1.60M
Revenue (ttm) n/a
Net Income (ttm) -388.28K
Shares Out 40.07M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Average Volume 2,146
Open 0.0400
Previous Close 0.0500
Day's Range 0.0400 - 0.0400
52-Week Range 0.0261 - 0.4600
Beta 0.42
RSI 36.14
Earnings Date Jul 14, 2025

About Agentix

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. The company offers AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind E... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country United States
Stock Exchange OTCMKTS
Ticker Symbol AGTX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.